Abstract: This digest covers some of the most important developments in the widely published discovery of malaria drugs between 2010 and 2012. The need to develop new antimalarial drugs is urgent. In order to reduce the symptoms, such medications may target the blood stage of the disease, the liver stage to prevent relapses, and the transmission stage to protect other humans. The blood stage pipeline is becoming stable, but this should not be a source of complacency, as a high standard is set by the current therapies. Drug development very liver-oriented activities and transmission phases are in their infancy, but the attention is earned as targeting these phases may be instrumental in eradicating malaria.
